Archive: January/February 2024

Evolving Applications of Liquid Biopsies in Gastrointestinal Cancers

Abstract: Liquid biopsy is a test that allows for the diagnosis and analysis of cancer by sampling cancer cells or byproducts present in biological fluids such […]

Risk Factors for Disease Progression and Treatment Goals in Polycythemia Vera

Abstract: Polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm characterized by the clonal proliferation of hematopoietic cells, leading to the overproduction of erythrocytes and the elaboration […]

Genomic Risk Stratification in Chronic Lymphocytic Leukemia

H&O  Which patients with chronic lymphocytic leukemia (CLL) require treatment? AW  A substantial proportion of patients with CLL can go for decades with no need for […]

Revisiting Immunotherapy in Endometrial Cancer

H&O  What are the limitations of chemotherapy for endometrial cancer? RE  The management of endometrial cancer has long relied on cytotoxic chemotherapy alone. This approach was […]

Letter From the Editor: Taking Leave

Over the past two years, two of my younger male colleagues have experienced the birth of their first child. These were wonderful times that brightened the […]

Sequencing Therapies: Optimal Treatment for HR+/HER2– Metastatic Breast Cancer

H&O  What are the options for first-line treatment of patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer? VK  The […]

The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma

H&O  What is glofitamab, and how does it work for patients with relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? LF  Glofitamab (Columvi, Genentech) is […]

Back to Archive